Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

Next Previous
Trial Profile

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Futibatinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Biliary cancer; Brain cancer; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Glioma; Head and neck cancer; Mesothelioma; Neuroblastoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Skin cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms FOENIX-101; FOENIX-CCA2
  • Sponsors Taiho Oncology

Most Recent Events

  • 20 Feb 2024 Status changed from active, no longer recruiting to completed.
  • 23 Sep 2023 This trial has been completed in Spain and Germany , according to European Clinical Trials Database record.
  • 04 Jul 2023 According to a Taiho Oncology media release, John Bridgewater is the Investigator and Senior Author of the NEJM publication.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top